United Therapeutics Corporation's (NASDAQ:UTHR) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock ...
Business Insider6h
United Therapeutics price target lowered to $460 from $475 at UBS
UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics is the firm’s top pick in Specialty Pharma in 2025, and ...
United Therapeutics scores FDA go-ahead for pig organ transplant clinical trial
Silver Spring’s United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be transplanted into humans. It's as significant for the ...
United Therapeutics president sells $3.5m in stock
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...
Arquitos Capital Management Q4 2024 Commentary
Arquitos returned 29.6% net of fees and expenses in 2024, compared to 25.0% for the S&P 500. Click here to read the full ...
H.C. Wainwright maintains AnaptysBio stock Neutral rating, $19 target
AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...